Joint Formulary & PAD

Avatrombopag - Immune thrombocytopenia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

PAD Profile

ChemicalSubstance :
Avatrombopag
Indication :
Immune thrombocytopenia
Group Name :
Keywords :
ITP, chronic immune thrombocytopenia, idiopathic thrombocytopenic purpura
Brand Names Include :
Doptelet
Important Information :

Haematology use only - treating primary chronic immune thrombocytopenia as per NICE TA853.

Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
3

Other Indications

Below are listed other indications that Avatrombopag is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Immune thrombocytopenia.

Committee Recommendations (2)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves the updated ITP pathway.

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends avatrombopag as a treatment option for the treating primary chronic immune thrombocytopenia in line with NICE TA853

Avatrombopag will be considered RED on the traffic light system. Prescribing will be by hospital specialists only

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.